A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development.
The abstract entitled ‘Interim Safety and Efficacy Data from a Phase 1 Clinical Trial of Sustained-release Axitinib Hydrogel Implant (OTX-TKI) in Wet AMD Subjects’ was presented at the American Academy of Ophthalmology (AAO) meeting in Chicago, USA, 30 September – 3 October 2022.
Questions:
- What are the limitations of intravitreal injections of anti-vascular endothelial growth factor agents in the treatment of wet age-related macular degeneration? (0:20)
- What is OTX-TKI and what are its potential advantages? (1:23)
- What were the aims, design and eligibility criteria of the study you presented? (2:11)
- What were the interim efficacy and safety findings? (3:21)
- What will be the next steps in the clinical development of OTX-TKI? (5:09)
Disclosures: Dilsher Dhoot is on the advisory board, a consultant for and has received honoraria from Alimera Sciences, Allergan, Apellis, Bausch and Lomb, Bayer, Coherus, Eyepoint, Genentech, Novartis, Regeneron, RegenXBio and Roche. He has received grant or research support from Allergan, Genentech and Regeneron and is on the speaker’s bureau for Alimera, Apellis, Eyepoint, Genentech and Regeneron.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of AAO 2022
Access more content on Macular Degeneration here
